Literature DB >> 28965114

Quality of Life in Children with Disorders of Sex Development.

Nalini M Selveindran1, Syed Zulkifli Syed Zakaria2, Muhammad Yazid Jalaludin3, Rahmah Rasat2.   

Abstract

BACKGROUND/AIMS: Disorders of sex development (DSD) are a heterogeneous group of rare conditions. Evidence-based treatment is challenged by a lack of clinical longitudinal outcome studies. We sought to investigate the quality of life of children with DSD other than congenital adrenal hyperplasia.
METHODS: The participants (aged 6-18 years) were 23 patients raised as males and 7 patients raised as females. Control data were obtained from representatives of the patients' siblings matched for age and gender. The Pediatric Quality of Life InventoryTM Version 4.0 (PedsQL) Generic Core Scales were used as the study tool.
RESULTS: In comparison with the reference data, the patient group had significantly lower overall PedsQL (p < 0.01) and school functioning (p < 0.01) scores. Also, the total PedsQL score was significantly lower in patients with DSD who were of female social sex as compared to the controls who were females. Family income, surgical procedures, degree of virilization, and mode of puberty did not influence the PedsQL scores.
CONCLUSION: This study revealed a poorer quality of life for patients with DSD as compared to the age-matched control group. This highlights the need for a skilled multidisciplinary team to manage this group of patients.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Children; Disorders of sex development; PedsQL questionnaire; Quality of life

Mesh:

Year:  2017        PMID: 28965114     DOI: 10.1159/000478780

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  1 in total

1.  Novel Genotype in Two Siblings with 5-α-reductase 2 Deficiency: Different Clinical Course due to the Time of Diagnosis.

Authors:  M Kocova; D Plaseska-Karanfilska; P Noveski; M Kuzmanovska
Journal:  Balkan J Med Genet       Date:  2019-12-21       Impact factor: 0.519

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.